Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells

BACKGROUND: Patients with triple negative breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumour relapse, due to the resistance to chemotherapy. These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs). Therefore, targeting BCSCs is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Jun, Raffa, Fatmah Al, Dai, Meiou, Moamer, Alaa, Khadang, Baharak, Hachim, Ibrahim Y., Bakdounes, Khldoun, Ali, Suhad, Jean-Claude, Bertrand, Lebrun, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288167/
https://www.ncbi.nlm.nih.gov/pubmed/30482914
http://dx.doi.org/10.1038/s41416-018-0287-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288167/
https://www.ncbi.nlm.nih.gov/pubmed/30482914
http://dx.doi.org/10.1038/s41416-018-0287-3

Ejemplares similares